

GenMark Diagnostics (USA): Constituent Deletion Changes in Russell Equal Weight Index Series

22 April 2021

Following the completion of the tender offer for GenMark Diagnostics (USA, constituent) by Roche Holdings, Inc., please see details of affected indexes and effective dates below:

Index	Effective From Start of Trading
Russell 2000 Equal Weight	27 April 2021

*Due to the absence of an active trading market, GenMark Diagnostics will be removed from the index at the tender offer terms of 24.05 USD per share held.

For further information please contact FTSE Russell Client Services at info@ftserussell.com or call:

Australia	+1800 653 680
Hong Kong	+852 2164 3333
Japan	+81 3 4563 6346
London	+44 (0) 20 7866 1810
New York	+1866 551 0617

Alternatively please visit our website at www.ftserussell.com

[Terms of Use](#) | Copyright © 2021 FTSE Russell